Testing YKST02 for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary IgA nephropathy (a kidney disease where a protein called IgA builds up in the kidneys).
- You have a certain amount of protein in your urine (proteinuria) at the screening visit.
- You are already on standard treatments for IgA nephropathy (like blood pressure medicines) and have been taking them for a while.
- Women who can get pregnant must have a negative pregnancy test and use effective birth control; men must also use effective birth control.
- You are willing to understand the study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests an experimental pill (NTQ5082) for people with IgA nephropathy, a kidney disease that can cause protein in the urine and kidney damage. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The treatment aims to reduce kidney damage, and this study will help determine if it is safe and effective.
Hear when a new Primary IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.